PML-RARA t(15;17) bcr1&bcr2, bcr3 Detection Kit
£1,363.00
The geneMAP™ PML-RARA t(15;17) Detection Kit is designed for the precise detection of the PML-RARA fusion gene, resulting from the translocation between chromosomes 15 and 17. This fusion gene is indicative of acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia (AML). The kit can identify all breakpoint cluster regions: bcr1, bcr2, and bcr3, using one-step RT-qPCR technology. With superior analytical sensitivity (log4 reduction) and accurate relative quantitation through multiplex PCR, this CE-IVD certified kit is compatible with FAM and VIC/HEX dual-color real-time PCR instruments, offering a vital diagnostic tool for leukemia.
The geneMAP™ PML-RARA t(15;17) Detection Kit is designed for the precise detection of the PML-RARA fusion gene, resulting from the translocation between chromosomes 15 and 17. This fusion gene is indicative of acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia (AML). The kit can identify all breakpoint cluster regions: bcr1, bcr2, and bcr3, using one-step RT-qPCR technology. With superior analytical sensitivity (log4 reduction) and accurate relative quantitation through multiplex PCR, this CE-IVD certified kit is compatible with FAM and VIC/HEX dual-color real-time PCR instruments, offering a vital diagnostic tool for leukemia.
- Superior Analytical Sensitivity: Achieves a log4 reduction, enabling the detection of low levels of the PML-RARA fusion transcript across all breakpoint cluster regions (bcr1, bcr2, bcr3).
- One-Step RT-qPCR Technology: Simplifies the testing process, making it both fast and user-friendly.
- Multiplex PCR: Facilitates accurate relative quantitation by comparing fusion transcripts against ABL1 gene expression, enhancing diagnostic precision.
- Instrument Compatibility: Designed for use with FAM and VIC/HEX dual-color real-time PCR instruments, ensuring broad applicability.
- CE-IVD Certification: Meets European standards for in vitro diagnostic medical devices, ensuring the kit’s reliability and quality.
- Efficient APL Diagnosis: Streamlines the detection of the PML-RARA fusion gene, crucial for diagnosing and monitoring acute promyelocytic leukemia (APL).
- High Sensitivity and Precision: Ensures reliable detection and quantitation of the fusion gene, even at minimal levels, facilitating early diagnosis and intervention.
- Ease of Use: The one-step RT-qPCR method reduces the complexity and time required for testing, enabling routine diagnostic use.
Leukemia Diagnosis and Monitoring: Specifically targets the PML-RARA fusion gene for patients suspected of or diagnosed with acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia (AML), playing a key role in diagnosis, prognosis, and treatment monitoring strategies.
- Technology: Utilizes one-step RT-qPCR with multiplex PCR for the detection and relative quantitation of the PML-RARA fusion transcript across bcr1, bcr2, and bcr3.
- Sensitivity: Features superior analytical sensitivity (log4 reduction) for detecting low levels of the target gene.
- Compatibility: Compatible with FAM and VIC/HEX dual-color real-time PCR instruments.
- Certification: Carries the CE-IVD mark, indicating compliance with EU regulations for in vitro diagnostic use.
Why Choose Clent
We strive to enable our customers to focus on the results of their work, rather than the tools they use. Need to speak with a member of our team? Get in touch today.
